Literature DB >> 11062791

Sertraline treatment of interferon-alfa-induced depressive disorder.

T M Schramm1, B R Lawford, G A Macdonald, W G Cooksley.   

Abstract

Interferon alfa therapy for chronic hepatitis C infection is commonly associated with neuropsychiatric symptoms, including depression. These side effects may necessitate reduction or even cessation of interferon alfa, but there is little information regarding the management of this important problem. We report 10 cases of interferon-alfa-induced depressive disorder treated with the selective serotonin reuptake inhibitor sertraline. All patients obtained rapid symptom relief without the need for reduction or cessation of interferon alfa.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11062791     DOI： 10.5694/j.1326-5377.2000.tb125687.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


  21 in total

1.  A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment.

Authors:  Amira Pierucci-Lagha; Jonathan Covault; Herbert L Bonkovsky; Richard Feinn; Christine Abreu; Richard K Sterling; Robert J Fontana; Henry R Kranzler
Journal:  Psychosomatics       Date:  2010 Mar-Apr       Impact factor: 2.386

2.  Major depressive disorder in hepatitis C: an open-label trial of escitalopram.

Authors:  Ondria C Gleason; William R Yates; Michelle A Philipsen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

3.  The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Authors:  Tarek Hassanein; Mitchell L Shiffman; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

4.  Management of Hepatitis C in HIV-infected Patients.

Authors:  Benigno Rodriguez; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

5.  A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C.

Authors:  J M Loftis; J M Wall; E Linardatos; S Benvenga; P Hauser
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

Review 6.  Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Authors:  Jennifer M Loftis; Annette M Matthews; Peter Hauser
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Preventing relapse of major depression during interferon-alpha therapy for hepatitis C--A pilot study.

Authors:  Ondria C Gleason; John C Fucci; William R Yates; Michelle A Philipsen
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

8.  Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care.

Authors:  Diana L Sylvestre; Jennifer M Loftis; Peter Hauser; Sander Genser; Helen Cesari; Nicolette Borek; Thomas F Kresina; Leonard Seeff; Henry Francis
Journal:  J Urban Health       Date:  2004-12       Impact factor: 3.671

9.  Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder.

Authors:  Peter Hauser; Benjamin J Morasco; Alex Linke; Dannell Bjornson; Samantha Ruimy; Annette Matthews; Aly Rifai; David W Indest; Jennifer M Loftis
Journal:  Psychosomatics       Date:  2009 Sep-Oct       Impact factor: 2.386

10.  Providing treatment for hepatitis C in an Australian district centre.

Authors:  A Ewart; L Harrison; B Joyner; A Safe
Journal:  Postgrad Med J       Date:  2004-03       Impact factor: 2.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.